Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987395 | 0.87 | XDH (0.66) | XDHALDH1A1KDM4ETHRATHRB | |
| SCHEMBL460614 | 0.79 | CDC7 (0.57) | CDC7DBF4ALDH1A1KDM4ELMNA | |
| SCHEMBL3709672 | 0.79 | CDC7 (0.52) | CDC7DBF4XDHALDH1A1KDM4E | |
| SCHEMBL17309802 | 0.79 | CDC7 (0.56) | CDC7DBF4ALDH1A1KDM4ELMNA | |
| SCHEMBL8867203 | 0.79 | CDC7 (0.56) | CDC7DBF4ALDH1A1KDM4ELMNA | |
| SCHEMBL3715639 | 0.78 | CDC7 (0.50) | CDC7DBF4XDHALDH1A1KDM4E | |
| SCHEMBL3709724 | 0.77 | CDC7 (0.51) | CDC7DBF4ALDH1A1KDM4ELMNA | |
| SCHEMBL8868127 | 0.77 | CDC7 (0.54) | CDC7DBF4ALDH1A1KDM4ELMNA | |
| SCHEMBL1985842 | 0.77 | JMJD6 (0.52) | ALDH1A1KDM4ELMNARAB9AMAPT | |
| SCHEMBL8867231 | 0.76 | CDC7 (0.48) | CDC7DBF4ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2338887-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | CDC7 3107/4885DBF4 3228/4885XDH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.